Search

Background There is scarce data of the impact of inflammatory indexes in locally advanced NSCLC, which is a highly heterogeneous illness. Choice of therapy is complex and often, combined CRT, either concurrently or sequentially is used. We aim to determine the impact of NLR monitoring in patients with stage III NSCLC treated with CRT. Methods Patients with stage III NSCLC treated with CRT were identified from Jan2010 to Dec2015 in our centre. NLR (neutrophils/lymphocytes) was retrospectively collected at baseline (B) and 5-6 weeks after CRT (C). It was considered a continuous variable and categorised (low Results 92 patients were included; median age 65.5 years (39-83); 85.87% were male and 90.3% had ECOG 0-1. Predominant histologies: adenocarcinoma (41.3%) and squamous-cell carcinoma (56.5%). Concurrent treatment in 78.9% patients and sequential in 21.1%. Median PFS and OS were 16.23 and 30.36 months (mo), in the overall population. On the multivariate analysis, the good prognostic group had significant longer median PFS and OS than the poor group: 33.9 vs 11.1 mo (p Table . 1466P Multivariate analysis PFS OS HR (95% CI) p value HR (95% CI) p value ECOG 1.65 (0.81 – 3.38) 0.169 2.55 (1.17 – 5.56) 0.018 Sequiential vs. Concurrent CRT 0.87 (0.41 – 1.81) 0.703 0.87 (0.38 – 1.97) 0.732 Baseline NLR 1.01 (0.83 – 1.23) 0.918 0.84 (0.66 – 1.07) 0.158 Post CRT NLR (low vs high) 1.08 (1.01 – 1.15) 0.018 1.11 (1.05 – 1.19) Prognostic groups (good vs poor) 3.00 (1.49 – 6.02) 0.002 2.83 (1.30 – 6.14) 0.009 Conclusions NLR could be used as a prognostic factor in stage III NSCLC especially when considering its dynamic evolution. Our results provide the opportunity to evaluate this inexpensive and reproducible index as a prognostic or predictive biomarker in prospective studies, particularly with the novel use of anti-PD-1/L1 after CRT. Legal entity responsible for the study Hospital Universitario Doctor Peset. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.